Envoy Medical files second FDA module for Acclaim cochlear implant
Envoy Medical submitted the second of four planned PMA modules for Acclaim CI to the FDA. The final clinical module is targeted for Q2 2027.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
TradingView, citing a press release from Envoy Medical, reported that the company submitted the second of four planned premarket approval (PMA) modules to the U.S. Food and Drug Administration for its Acclaim cochlear implant. The device has received Breakthrough Device designation.
The second filing follows the first module submitted in June 2026. Envoy Medical is targeting the final clinical module for submission in Q2 2027. Its U.S. pivotal trial is still underway, and the clinical results will be relevant to approval prospects and the timing of commercialization.
According to TradingView, the FDA review is progressing through continued company interactions rather than a single complete filing. The report is based on an Envoy Medical release distributed by TMX Newsfile and may contain inaccuracies.
why it matters
The next major market-relevant milestones are pivotal-trial results, submission of the final clinical module in Q2 2027 and FDA feedback on earlier modules. Breakthrough Device status may support prioritized review, while approval remains dependent on regulatory assessment and clinical outcomes.
instruments
sources
- Envoy Medical Inc. (COCH) Submits Second PMA Module for Acclaim CI — TradingView, 12 October 2026 at 12:30 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗